Vedolizumab Latest Market Report 2025
Global Info Research‘s report offers an in-depth look into the current and future trends in Vedolizumab, making it an invaluable resource for businesses involved in the sector. This data will help companies make informed decisions on research and development, product design, and marketing strategies. It also provides insights into Vedolizumab’ cost structure, raw material sources, and production processes. Additionally, it offers an understanding of the regulations and policies that are likely to shape the future of the industry. In essence, our report can help you stay ahead of the curve and better capitalize on industry trends.
According to our (Global Info Research) latest study, the global Vedolizumab market size was valued at US$ 6010 million in 2024 and is forecast to a readjusted size of USD 9457 million by 2031 with a CAGR of 6.7% during review period.
In this report, we will assess the current U.S. tariff framework alongside international policy adaptations, analyzing their effects on competitive market structures, regional economic dynamics, and supply chain resilience.
Vedolizumab is a humanized monoclonal antibody targeting α4β7 integrin, which inhibits the interaction between this integrin and the gut-specific adhesion molecule MAdCAM-1, thereby preventing inflammatory lymphocytes from migrating to the gastrointestinal tract and reducing intestinal inflammation. It is primarily indicated for the treatment of moderate to severe active inflammatory bowel diseases, including ulcerative colitis and Crohn’s disease, and is administered via intravenous infusion. Vedolizumab offers tissue-specific action, minimizing systemic immunosuppression risks. In 2024, the global sales volume of vedolizumab reached 2.485 million doses, with an average price of 2,350 USD per dose.
Regional market landscape
The global vedolizumab market exhibits a distinct regional distribution, with North America accounting for 45.8%, Europe 33.2%, Asia-Pacific 14.5%, Latin America 4.3%, and the Middle East & Africa 2.2%. 90% administration is via intravenous infusion, and distribution channels are primarily hospitals and clinics at 87.5%, retail pharmacies 10.2%, and other channels 2.3%. These fixed regional and channel proportions directly affect production planning, inventory strategy, and market entry prioritization.
Key manufacturers and industry competition
The vedolizumab market is dominated by the originator Takeda, which maintains a strong global supply chain and production capacity, while biosimilar manufacturers such as Celltrion, Samsung Bioepis, and Sandoz have obtained regulatory approvals in certain regions and are gradually scaling production. Upstream, the supply chain includes recombinant antibody cell lines, culture media, downstream purification processes, and lyophilization excipients, with major CDMOs and raw material suppliers ensuring stable supply of the antibody and critical excipients. Downstream distribution is managed by hospitals, wholesalers, and distribution networks. Due diligence must assess upstream raw material and process stability, downstream concentration, and potential supply risks.
Technology trends and innovation direction
Current technological trends focus on optimizing antibody expression systems, improving process efficiency, enhancing stability of lyophilized and liquid formulations, and integrating digital process monitoring and process analytical technology (PAT). Biosimilar companies are improving downstream purification, increasing bioequivalence testing efficiency, and optimizing cold-chain logistics to reduce costs and improve product consistency, while also making minor innovations in administration convenience and patient adherence.
Policy and industry drivers
Regulatory policies and drug accessibility are primary drivers shaping the market, including biosimilar approval frameworks, pricing negotiations, reimbursement adjustments, patent and market exclusivity management, GMP certification of production facilities, and clinical safety monitoring requirements. These factors directly affect product launch speed, market share, and price elasticity, while policies encouraging domestic CDMO investment, import substitution, and supply chain stability can reshape industry competition.
Outlook
In the coming years, as multiple biosimilar manufacturers expand capacity and gain regulatory approvals, the market is expected to move toward diversified supply and increased pricing pressure, though regional supply shortages may intermittently occur due to raw material volatility or policy changes. For investors and acquirers, focus will shift from individual financial performance to robustness of upstream antibody supply, redundancy of critical excipient channels, stability of downstream distribution, and long-term quality and compliance systems, with firms demonstrating strength across these areas positioned to gain competitive advantage.
This report is a detailed and comprehensive analysis for global Vedolizumab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Our Vedolizumab Market report is a comprehensive study of the current state of the industry. It provides a thorough overview of the market landscape, covering factors such as market size, competitive landscape, key market trends, and opportunities for future growth. It also pinpoints the key players in the market, their strategies, and offerings.
Request PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)
https://www.globalinforesearch.com/reports/2995555/vedolizumab
The research report encompasses the prevailing trends embraced by major manufacturers in the Vedolizumab Market, such as the adoption of innovative technologies, government investments in research and development, and a growing emphasis on sustainability. Moreover, our research team has furnished essential data to illuminate the manufacturer's role within the regional and global markets.
The research study includes profiles of leading companies operating in the Vedolizumab Market:
The report is structured into chapters, with an introductory executive summary providing historical and estimated global market figures. This section also highlights the segments and reasons behind their progression or decline during the forecast period. Our insightful Vedolizumab Market report incorporates Porter's five forces analysis and SWOT analysis to decipher the factors influencing consumer and supplier behavior.
Segmenting the Vedolizumab Market by application, type, service, technology, and region, each chapter offers an in-depth exploration of market nuances. This segment-based analysis provides readers with a closer look at market opportunities and threats while considering the political dynamics that may impact the market. Additionally, the report scrutinizes evolving regulatory scenarios to make precise investment projections, assesses the risks for new entrants, and gauges the intensity of competitive rivalry.
Major players covered: Takeda Pharmaceutical、 Fresenius Kabi
Vedolizumab Market by Type: Intravenous Infusion、 Injection Pen
Vedolizumab Market by Application: Crohn's Disease、 Ulcerative Colitis、 Others
Key Profits for Industry Members and Stakeholders:
2. Which regulatory trends at corporate-level, business-level, and functional-level strategies.
3. Which are the End-User technologies being used to capture new revenue streams in the near future.
4. The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
5. One can increase a thorough grasp of market dynamics by looking at prices as well as the actions of producers and users.
6 Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Vedolizumab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Vedolizumab, with price, sales, revenue and global market share of Vedolizumab from 2020 to 2025.
Chapter 3, the Vedolizumab competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Vedolizumab breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2020 to 2024.and Vedolizumab market forecast, by regions, type and application, with sales and revenue, from 2025 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Vedolizumab.
Chapter 14 and 15, to describe Vedolizumab sales channel, distributors, customers, research findings and conclusion.
About Us:
Global Info Research
Web: https://www.globalinforesearch.com
CN: 0086-176 6505 2062
HK: 00852-58030175
US: 001-347 966 1888
Email: report@globalinforesearch.com
Global Info Research is a company that digs deep into global industry information to support enterprises with market strategies and in-depth market development analysis reports. We provides market information consulting services in the global region to support enterprise strategic planning and official information reporting, and focuses on customized research, management consulting, IPO consulting, industry chain research, database and top industry services. At the same time, Global Info Research is also a report publisher, a customer and an interest-based suppliers, and is trusted by more than 30,000 companies around the world. We will always carry out all aspects of our business with excellent expertise and experience.
